To determine whether treatment with recombinant human tissue factor pathway inhibitor (TFPI), an inhibitor of the extrinsic coagulation pathway, can improve survival in a clinically relevant model of gram-negative sepsis, rabbits were given an intraperitoneal inoculation of a suspension containing hemoglobin (40 mg/mL), porcine mucin (150 mg/mL), and viable Escherichia coli O18:K1 (1.0 { 0.5 1 10 5 cfu/kg). Treatment with gentamicin (5 mg/kg every 12 h for five doses) was instituted 4 h after induction of peritonitis. At the same time point, rabbits were randomized to receive a 24-h infusion of vehicle or one of three different doses of TFPI. Treatment groups, 7-day survival rates, and significance versus control were as follows: control, 1 of 20; TFPI LOW DOSE (0.1 mg/kg, then 1 mg/kg/min), 3 of 12 (P Å .14); TFPI MID DOSE , (0.5 mg/kg, then 5 mg/kg/min), 7 of 12 (P Å .002); TFPI HIGH DOSE (10 mg/kg, then 10 mg/kg/min), 4 of 13 (P Å .04). Thus, delayed treatment with TFPI improves survival in septic rabbits.
Derangements in clotting and coagulation are common comleading to the formation of a tissue factor -factor VIIa complex plications of gram-negative sepsis [1] . Thrombocytopenia octhat is capable of activating both factors X and IX [13] . curs in 18% -74% of patients with sepsis [2 -5] . Frank dissemTissue factor pathway inhibitor (TFPI) is a naturally ocinated intravascular coagulation (DIC), while less common than curring inhibitor of tissue factor -initiated coagulation [19] . simple thrombocytopenia, is nevertheless a very serious and TFPI, also known as extrinsic pathway inhibitor or lipoproteinfairly frequent occurrence in patients with overwhelming gramassociated coagulation inhibitor, is a member of a large family negative infections [6 -10] . Severe abnormalities in coagulation of serine protease inhibitors (Kunitz-type protease inhibitors). have been implicated as prognostic variables predicting a poor TFPI inhibits the tissue factor -factor VIIa complex via an outcome in patients with sepsis [5, 8, 11] . Although the mechaordered sequence of reactions in which the active site of factor nisms responsible for thrombocytopenia and/or DIC in sepsis Xa binds to TFPI and then the factor Xa -TFPI complex, in remain to be elucidated completely, currently available data the presence of ionized calcium and factor Xa, binds the tissue suggest that events initiated by tissue factor are particularly factor -factor VIIa complex [19] . In humans and other species, important [12] .
the normal circulating concentration of TFPI is Ç100 ng/mL Tissue factor is a 263-aa transmembrane glycoprotein [13] . [19] . Circulating TFPI levels are reportedly slightly elevated The expression of tissue factor on vascular endothelial cells in patients with sepsis [20, 21] and the acute respiratory distress and cells of the monocyte/macrophage lineage is increased syndrome [22] , although low plasma TFPI levels have been following exposure to lipopolysaccharide, a component of the detected in some patients with gram-negative bacteremia and outer cell wall of gram-negative bacteria, and/or certain proin-DIC [20] . flammatory cytokines, notably tumor necrosis factor-a and in-TFPI has been sequenced and cloned [23] . In a primate terleukin-1, which have been implicated in the pathogenesis of model of lethal gram-negative bacteremia, treatment with resepsis [14 -18] . Tissue factor binds and activates factor VII, combinant TFPI has been shown to significantly improve survival, even when administration of the protein is delayed for several hours after the induction of sepsis [24, 25] . In the animal model used for these studies, septic shock was induced a continuous infusion of the agent (10 mg/kg/min) for 12 h. ConMaterials and Methods trols (n Å 10) received similar volumes (bolus plus infusion) of Animals. New Zealand White rabbits (11-14 weeks old; 2.8-the vehicle for TFPI. 3.1 kg; Millbrook Associates, Amherst, MA) were maintained 1/
In the second series of experiments, the treatment group (n Å cage in a temperature-controlled room with a 12-h light-dark cycle 8) was given a bolus of TFPI (1 mg/kg) over 15 min at 4 h after and permitted free access to water and a standard chow. induction of sepsis, followed by a continuous infusion of 10 mg/ Bacteria. For these studies, we used a species and strain of kg/min for 24 h. The control rabbits (n Å 8) received a similar bacteria, E. coli O18:K1, that is frequently isolated from patients amount of the vehicle. with gram-negative bacteremia [26] . The initial inoculum was a
In the third series of experiments, we studied 4 groups of anigift from H. Shaw Warren (Massachusetts General Hospital, Bosmals: control (n Å 20), TFPI LOW DOSE (n Å 12), TFPI MID DOSE (n ton). This isolate is susceptible to gentamicin in vitro. For each Å 12), and TFPI HIGH DOSE (n Å 13). All groups received a bolus experiment, a frozen aliquot of the organisms was thawed and of either buffer (control group) or TFPI at 4 h after induction of used to inoculate 125 mL of medium (Bacto Nutrient Broth; Difco, sepsis, followed by a continuous infusion of the vehicle or TFPI Detroit). After being incubated with shaking at 37ЊC for 15 h, the for 24 h. The TFPI LOW DOSE group received a 0.1-mg/kg bolus of broth was centrifuged (2500 g at 4ЊC for 10 min). The pellet was TFPI followed by an infusion of 1 mg/kg/min. The TFPI MID DOSE resuspended in 50 mL of normal saline. After two more cycles of group received a 0.5-mg/kg bolus of TFPI followed by an infusion centrifugation and resuspension, the final concentration of bacteria at 5 mg/kg/min. The TFPI HIGH DOSE group received a 10-mg/kg was estimated nephelometrically by measuring optical density at bolus of TFPI followed by 10 mg/kg/min. 620 nm and comparing the result with a previously generated
In all three series of experiments, both control and TFPI-treated standard curve plotting optical density against viable colony-formrabbits received intravenous gentamicin (5 mg/kg/dose) every 12 ing units.
h for five doses or until death. In the first series, treatment with Recombinant human TFPI. Nonglycosylated TFPI containing gentamicin was initiated at 6 h after induction of sepsis, whereas an additional alanine residue at the amino terminus of the wild in the second and third series of experiments, treatment with the type molecule was obtained from Chiron/Searle (Emeryville, CA).
antibiotic was started at 4 h. The protein was expressed in E. coli as previously described [27] Hematologic and biochemical assays. Blood lactate concenand was formulated in a buffer consisting of 20 mM citrate, 200 trations were determined by use of a commercial analyzer (Yellow mM arginine, 150 mM NaCl, and 0.01% Tween 80 (pH 6.0). The Spring Instruments, Yellow Springs, OH). Circulating white blood same buffer, but without TFPI, was used throughout the expericell (WBC) and platelet counts were determined by use of a particle ments as the control solution. Endotoxin levels in the TFPI preparacounter (Coulter Electronics, Miami). Arterial blood gases were tions were £0.8 EU/mL. measured with an analyzer from Instrumentation Laboratories Surgical preparation. Rabbits were anesthetized with intra-(Lexington, MA). Assays for various parameters of coagulation muscular ketamine hydrochloride (35 mg/kg) and xylazine (5 mg/ were done by use of a device from Instrumentation Laboratories kg). Via a cervical cutdown, polyethylene catheters were posi-(model ACL 3000/). tioned in a carotid artery and jugular vein. The catheters were Statistical analyses. Except for survival data, results are preexteriorized on the dorsal surface of the neck and secured in place sented as means { SEs. Kaplan-Meier survival curves were anawith 3-0 suture. The catheters were flushed with 2 mL of heparinlyzed with the Breslow test. Fisher's exact test was used to deterized saline (0.5 U/mL) and capped. Via a 1-cm midline laparotomy mine the significance of differences in survival at 7 days between incision, the peritoneal cavity was inoculated with 10 mL of a treated and control groups. All other results were analyzed by onesuspension containing hemoglobin (40 mg/mL; Sigma, St. Louis), way or two-way (group and time) repeated-measures analysis of porcine mucin (150 mg/mL; Sigma), and a known number of viable variance, with post hoc analyses being done with the Student-E. coli. For the first two series of experiments, the inoculum conNewman-Keuls test. Results were considered significant for P tained 3.1 { 0.2 1 10 4 cfu/kg viable bacteria. In the third series õ .05. of experiments, the inoculum contained 1.0 { 0.5 1 10 5 cfu/kg viable bacteria. After implantation of the bacterial suspension, the incision was closed with 3-0 silk suture. The rabbits were returned TFPI (1 mg/kg bolus plus 10 mg/kg/min for 12 h) was started Experimental design. We typically conducted one experiment at 6 h. As evident from the pooled data for all animals (i.e., per week. For each experiment, 6 rabbits, carefully matched for both vehicle-and TFPI-treated) shown in table 1, the rabbits age and weight, were prepared and studied as a group. In each manifested obvious signs of sepsis, such as leukopenia, hyperexperiment, 2 of the 6 animals always received the buffer formulalactatemia, and metabolic acidosis, by the time treatment was tion without TFPI and served as concurrent controls. Overall, we initiated. Nevertheless, as shown in figure 1 , treatment with conducted three series of experiments.
TFPI significantly prolonged mean survival time from 38 h in
In the first series, rabbits were randomly allocated to either controls to 81 h in drug-treated rabbits (P Å .05). At 7 days, TFPI-treated or control groups. The treated rabbits (n Å 11) resurvival was 1 of 10 in vehicle-treated rabbits and 4 of 11 in ceived an initial bolus of TFPI (1.0 mg/kg) over 15 min at 6 h after the induction of sepsis. The bolus of TFPI was followed by TFPI-treated rabbits.
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01-12-98 09:08:10 jinfa UC: J Infect was induced at 0 h and treatment was initiated at 4 h. * P õ .05 vs. we sought to obtain more detailed information regarding the Experiment 2. The goal of the second experiment was to effects of treatment with TFPI in sepsis by measuring several determine if earlier and more prolonged treatment with TFPI physiologic parameters over time in animals treated with either (i.e., 1 mg/kg bolus plus 10 mg/kg/min for 24 h started at 4 h) vehicle or the experimental agent. Accordingly, rabbits were would afford a greater improvement in survival in rabbits with treated beginning at 4 h with gentamicin plus either vehicle or gram-negative peritonitis than was observed in experiment 1.
one of three different doses of TFPI. As shown in figure 3 , all As in the previous experiment, rabbits manifested signs of three doses of TFPI significantly improved survival compared sepsis (leukopenia, respiratory alkalosis) at the time treatment with that in concurrent vehicle-treated controls. Seven-day surwith antibiotics plus vehicle or TFPI was initiated. Treatment vival rates for the 4 study groups were as follows: vehicle with TFPI dramatically improved 7-day survival from 0 of 8 controls, 1 (5%) of 20; TFPI LOW DOSE , 3 (25%) of 12 (P Å .14 in controls to 7 (87.5%) of 8 in animals treated with the recomvs. control); TFPI MID DOSE , 7 (58.3%) of 12 (P Å .002 vs. binant protein (P Å .006; figure 2). Mean survival time was control); TFPI HIGH DOSE , 4 (30.8%) of 13 (P Å .04). Mean significantly increased from 48 h in controls to 149 h in TFPIsurvival times for the 4 study groups were as follows: vehicle treated rabbits (P Å .001).
controls, 27 h; TFPI LOW DOSE , 68 h; TFPI MID DOSE , 109 h; Experiment 3. There were two goals of the third experi-TFPI HIGH DOSE , 93 h. Survival was significantly prolonged comment. First, we sought to determine if doses of TFPI lower than 1 mg/kg bolus plus 10 mg/kg/min would be sufficient to improve survival in rabbits with gram-negative sepsis. Second, Figure 3 . Effect of treatment with TFPI (3 different dosing regimens) or vehicle on survival in rabbits with gram-negative peritonitis. Sepsis was induced at 0 h and treatment was initiated at 4 h. Groups are as follows: short dashed rule, TFPI LOW DOSE ; long dashed rule, Figure 1 . Effect of treatment with TFPI (solid line) or vehicle (broken line) on survival in rabbits with gram-negative peritonitis. Sepsis TFPI MID DOSE ; solid rule, TFPI HIGH DOSE ; alternating short and long dashes, control. * Significant (P õ .05) difference in mean survival was induced at 0 h and treatment was initiated at 6 h. * P õ .05 vs. controls (Breslow test).
time between indicated group and controls (Breslow test).
/ 9d41$$mr42 01-12-98 09:08:10 jinfa UC: J Infect Circulating WBC counts were similar in all groups at baseline (figure 4A with respect to the 0-h value in all groups. However, at 10 and 16 h, WBC counts tended to return toward normal in all 3 TFPI-treated groups, whereas WBC counts continued to decline in vehicle-treated controls. Platelet counts were similar among groups at baseline but decreased significantly over time in the control group (figure 1B). In contrast, platelet counts remained constant over time in septic rabbits treated with TFPI and were significantly higher than those in time-matched controls at 10 and 16 h. Table 2 presents mean arterial blood pressure and partial pressure of oxygen in arterial blood (PaO 2 ) for control rabbits and rabbits treated with TFPI. Results obtained at 0 h are not presented (although the measurements were obtained), because the rabbits were deeply anesthetized at that time point and blood pressure and PaO 2 were low in all animals on that basis. Whereas blood pressure tended to increase over time in TFPItreated rabbits, the opposite was true in controls. Compared with values in controls, mean arterial pressure values were significantly higher at 10 and 16 h in the TFPI HIGH DOSE and TFPI MID DOSE groups but not the TFPI LOW DOSE group. By 4 h, PaO 2 values were normal and were similar in all 4 groups. However, at 10 and 16 h, PaO 2 values were significantly lower in the vehicle-treated group than in any of the TFPI-treated groups.
Base excess was similar and positive in all groups at baseline (figure 5A). Base excess decreased in all groups over time, although severe metabolic acidosis was evident from 0 to 16 h only in vehicle-treated controls. Values of base excess at 10 arterial pH was similar and normal in all groups at baseline, in the groups treated with TFPI ( figure 5C ). Blood lactate at 0 and 4 h (i.e., before and after the onset of sepsis but before the institution of any therapeutic interventions) have been concentration was 1.2 { 0.2 mM at 0 h in the control group and increased significantly, to 3.8 { 0.4 mM, at 16 h (figure pooled. In addition, for other analyses (table 3) , data for the 3 TFPI-treated groups have been pooled for comparison with 5D). In contrast, blood lactate concentration did not change significantly over time in any of the TFPI-treated groups. At data from the vehicle-treated group. For all rabbits, prothrombin time increased slightly, from 7.3 { 0.3 s at 0 h to 7.9 { 10 and 16 h, blood lactate concentrations were significantly lower in all of the TFPI-treated groups than in the control 0.3 s at 4 h (n Å 40; P Å .55). Similarly, partial thromboplastin time increased slightly, from 59.3 { 12.0 s at 0 h to 63.4 { group.
A number of parameters related to blood coagulation were 11.0 s at 4 h (n Å 39; P Å .21). Circulating fibrinogen levels decreased from 283 { 30 mg/dL at 0 h to 183 { 26 mg/dL at measured. However, because a number of specimens were lost when a freezer thawed during a power outage, sample sizes 4 h (n Å 40; P Å .08). During the interval from 0 to 4 h, circulating levels of factor V activity decreased substantially, were too small for detailed group-by-group analyses of data from all 4 treatment groups. Accordingly, data from all animals from 1842 { 125 to 468 { 43 percentage activity units (n Å used as an adjuvant to therapy with conventional antimicrobial chemotherapy. The beneficial effect of treatment with TFPI NOTE. Control, n Å 3; TFPI, n Å 8. Results shown are pooled data from was evident even when therapy was delayed as long as 4 -6 h all TFPI-treated groups. PT, prothrombin time; PTT, partial thromboplastin time. For factor X and fibrinogen, P for group 1 time effect by two-way after the onset of infection (i.e., after unambiguous signs of repeated-measures analysis of variance was .02 and .07, respectively. For all sepsis were already present). In addition to improving survival, other coagulation factors or parameters, P was not significant. treatment with TFPI also had beneficial effects on a number of different physiologic parameters, including arterial blood pressure, arterial oxygenation, and peripheral blood platelet 24; P Å .03), and levels of factor VII activity decreased from and leukocyte counts. While dosing of TFPI extended over a 453 { 78 to 320 { 54 percentage activity units (n Å 24; P Å 10-fold range, only a 3-fold difference in circulating TFPI .07). Circulating levels of factor X increased from 482 { 72 concentrations was observed between the highest and lowest to 597 { 88 percentage activity units (n Å 40; P Å .30).
doses of the compound studied (data not shown). As shown in table 3, treatment with TFPI resulted in higher Since circulating concentrations of TFPI range from considfibrinogen and factor X levels over the first 16 h of observation.
erably less than normal to about twice normal in many cases Values for prothrombin time, partial thromboplastin time, facof sepsis [20, 21] , it is reasonable to wonder why administration tor V, and factor VII were similar between groups.
of exogenous TFPI has been found to improve survival in At necropsy, the lungs of nonsurvivors were grossly edematwo different animal models of sepsis. Unfortunately, presently tous, and the airways were filled with pink, frothy fluid. The available data are insufficient to answer this question definikidneys were hemorrhagic and congested. The liver typically tively. In a previously published study, treatment with recombicontained abscesses that grew out E. coli. Abscesses were presnant TFPI was shown to improve survival when infused in ent throughout the peritoneal cavity. In contrast, 7-day surviseptic baboons at a dosage designed to achieve a circulating vors showed evidence of minimal pulmonary congestion. Small TFPI concentration of 2000 ng/mL (i.e., Ç20 times greater scattered abscesses were often present in the peritoneal cavity, than normal) [24] . However, preliminary data from ongoing but other solid organs (adrenals, liver, spleen) were grossly studies in our laboratory suggest that survival in septic rabbits normal.
is associated with circulating TFPI levels in the 300 -1000 ng/mL range (i.e., Ç3-to 10-fold greater than normal [unpublished data]). Accordingly, relatively small increases in circuDiscussion lating TFPI levels may be sufficient to provide protection against potentially lethal consequences of gram-negative infecThree lines of evidence support the notion that tissue factormediated events are important in the pathogenesis of sepsis.
tion. Furthermore, TFPI exists in vivo in three separate compartments: sequestered in platelets, bound to endothelial cells, First, injection of human volunteers or experimental animals with lipopolysaccharide or tumor necrosis factor-a results in and circulating in plasma [19] . It is possible, therefore, that measurements of circulating TFPI provide an incomplete prothe generation of thrombin despite normal plasma levels of markers of intrinsic pathway activation (e.g., factor XIIa -C1 file of the functional availability of TFPI as an inhibitor of and lapine proteins, although some important differences have been reported [44] . For example, lapine TFPI has a glycosylaThe rabbit sepsis model used for these studies is characterized by the following features: Survival is the primary end tion site at residue 245 (asparagine), which is absent from the human protein [44] . This observation is consistent with data point; sepsis is caused by a true infection (rather than the injection of purified endotoxin or some other microbial prodshowing that rabbit TFPI is more extensively glycosylated than is human TFPI [45] . Whereas human TFPI binds to lipoprouct); sepsis is induced by a relatively small initial inoculum (i.e., the microbes proliferate in vivo, leading ultimately to a teins, the lapine form does not [45] . Human recombinant TFPI expressed in E. coli (i.e., the form of the protein used in the potentially lethal burden of bacteria); sepsis is associated with a defined focus of infection (rather than caused by an intravenous present study) has essentially the same biologic activity in normal rabbit plasma as in normal human plasma (unpublished infusion of viable microbes); the magnitude of the septic challenge is under tight experimental control; the experimental data). The present studies, while clearly supporting the view that agent (i.e., TFPI) is evaluated as adjunct to conventional antimicrobial chemotherapy; treatment with the experimental agent TFPI has considerable potential as an adjuvant agent for the treatment of gram-negative sepsis in patients, provide little is instituted after the onset of clinical signs of sepsis; and sepsis is caused by a clinically relevant pathogenic organism. In this information regarding the mechanism(s) underlying the agent's therapeutic effects. Treatment with TFPI ameliorated the conmodel, sepsis is induced by implanting in the peritoneal cavity a known quantity of viable organisms suspended in a mixture sumption of fibrinogen and factor X induced by sepsis in rabbits, suggesting that inhibition of DIC may be a factor contribcontaining hemoglobin and mucin. Both hemoglobin [36 -39] and mucin [37, 40, 41] are well-known ''adjuvants'' capable uting to the salutary effects of the agent. Lactate levels were lower and base excess levels were higher in TFPI-treated comof markedly diminishing the size of the initial inoculum of organisms required to cause mortality in experimental infecpared with vehicle-treated rabbits, suggesting that the apparent increases in anaerobic metabolism induced by sepsis were tions. These adjuvants are thought to promote the proliferation of the bacteria in vivo [39] or interfere with the host's defenses ameliorated by the recombinant protein. These findings might be interpreted as being consistent with prevention of DICagainst the infectious challenge [36, 42, 43] (or both).
Treatment with the experimental agent (or the appropriate induced derangements in microvascular perfusion in TFPItreated rabbits. However, lactate production can increase in control substance) was started at 4 h. By this time point, the animals showed obvious clinical manifestations of systemic sepsis for reasons unrelated to the adequacy of tissue perfusion [46] , and, therefore, the underlying mechanism(s) responsible inflammation (conjunctival injection, lethargy) as well as laboratory evidence of sepsis (leukopenia). As would be the case for the lower blood lactate levels in TFPI-treated compared with control septic rabbits remains to be established. in the clinical setting, treatment with TFPI (or the control substance) was started at the same time as the initiation of therapy Although experiment 3 was designed as a dose-response study, we were unable to detect clear dose-dependent effects with an appropriate antibiotic. Thus, TFPI was evaluated in the context of standard antimicrobial chemotherapy.
on survival or various physiologic parameters. While the middle dose of TFPI (0.5 mg/kg bolus plus 5 mg/kg/min for 24 h) As recently pointed out by Cross et al. [26] , sepsis models should use pathogenic microorganisms endowed with features seemed to be the most effective of the three doses studied, differences among groups were too small or too inconsistent (e.g., presence of a polysaccharide capsule) that interfere with the opsonophagocytic mechanisms of the host. It is noteworthy to achieve statistical significance. At present, we can offer no adequate explanation for the apparent lack of a dose-response in this regard that of the ú170 identified O-specific serotypes of E. coli, only Ç12 are commonly identified in patients with relationship. Two possibilities, however, must be considered. First, even the lowest dose of TFPI used may have been greater bacteremias caused by the microbial species [26] . Interestingly, many of the strains of E. coli that have been used commonly than the level providing maximal benefit with respect to survival in rabbits with gram-negative peritonitis. Second, higher in laboratory models of sepsis lack the virulence factors associated with ability to survive and proliferate in vivo [26] . The doses of TFPI may have been associated with toxicity (manifested as decreased survival), which masked any improvement strain of E. coli used for the present study, O18:K1, is commonly responsible for bloodborne infections in humans and is in the therapeutic action of the agent. In summary, we showed herein that recombinant TFPI sighighly pathogenic [26] .
Because the rabbit has been widely used for studies of liponificantly improves survival and other physiologic parameters in a very stringent and clinically relevant animal model of focal polysaccharide-induced inflammation and coagulation, the
